Wednesday, September 12, 2018 Daily Archives

Exclusive: Samsung BioLogics poised to enter cell therapy space

by

After building three large-scale biomanufacturing plants, CDMO Samsung BioLogics has told BioProcess Insider it is adding single-use capacity and is considering expanding into stem cell therapy services. It has been nine years since Samsung BioLogics entered the third-party biologics space, in which time it has brought two commercial biomanufacturing facilities online with a third expected to be fully validated by the end of this year. When operational, the firm’s site in Incheon, South Korea will boast a total of 362,000…

September 12, 2018

Sanofi deal shows demand for CHO alternatives, says Dyadic

by

Sanofi-Aventis Deutschland has teamed with Dyadic to test the potential of the C1 fungus-based expression system for the manufacture of biologics and vaccines. The fully funded proof of concept research deal will see Sanofi-Aventis use Dyadic International’s C1 platform to overcome specific gene expression challenges across some of its vaccine and protein-based biologics “Sanofi sees huge value in C1 and the future of bioprocessing and biomanufacturing efficiencies with such a power horse and we are excited for the collaboration as…

September 12, 2018